ArticleIJID regions2025
Acceptability of a chikungunya vaccine and dengue vaccine among travelers in Martinique (French West Indies), for the travel and for their home territory.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The incidence of chikungunya and dengue is increasing worldwide. Vaccines are now available against these two arboviral diseases. Methods: We evaluated the acceptability of live chikungunya and dengue vaccines (VLA1553 and TAK-003) among users of Martinique's travel clinics from January to April 2025. We asked whether they would want these vaccines for travel to areas with exposure risk and/or for their home territory. Results: While planning travel, 41% of respondents expressed interest in the chikungunya vaccine, and 55% were interested in the dengue vaccine. For the Martinique territory, 55% were willing to receive the chikungunya vaccine, and 58% were willing to receive the dengue vaccine. Conclusions: In both contexts (travel and home territory), acceptability was higher for dengue than for chikungunya vaccination. Acceptability for both vaccines was also higher for the home territory than for travel to areas with exposure risk. Few data are available on chikungunya vaccine acceptability. We found similar acceptability for this vaccine in Martinique as reported in the United States Virgin Islands (56%), an overseas territory of the United States in the Caribbean, and in La Réunion, another French overseas territory in the Indian Ocean (60.5% in the hypothetical full-reimbursement scenario).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.